GEn1E Lifesciences YC Başvurusu

Summer 2019Active

GEn1E Lifesciences, Healthcare şirketi olarak Summer 2019 grubunda Y Combinator'dan geçti. Aşağıda: şirketin ne yaptığı, kimin kurduğu ve gerçek YC formunda yeniden yapılandırılmış YC başvurusu.

YC grubu: Summer 2019
Sektör: HealthcareTherapeutics
Durum: Active
Lansmanı Yapıldı: 2022

Kurucular

Ritu LalFounder

GEn1E Lifesciences ne yapar

GEn1E Lifesciences is a Clinical-stage, multi-target company with a unique AI platform. We develop novel, next-generation, immunomodulatory therapies for rare & inflammatory diseases with no effective treatments. Our team is supercharging the drug development cycle by applying AI to multiple-mechanism-of-action protein targets and their natural platform capabilities - creating novel therapeutics at an unprecedented pace. Our AI platform has enabled us to develop a purpose-built therapy for ARDS to reduce its $20 billion cost on society (just in the USA). GEn1E has built a rich pipeline of 21+ novel and selective immunomodulators and has plans to accelerate 2 additional devastating diseases (beyond their lead indication) to IND in the next 12 months. Our AI platform enables tremendous pace and capital efficiency as demonstrated by our progress in ~2 years with seed capital - a stark contrast to the typical spend of $100M+ and 7+ years exhibited in the pharmaceuticals / biotech industry. With ~90% of rare diseases having no therapeutic treatment at all, GEn1E is taking a giant swing that will hopefully bring life-saving therapies to the lives of patients in need. The team at GEn1E has decades of experience in drug development and machine learning. We graduated from YCombinator and Stanford-StartX in late 2019. We are based in Palo Alto, CA.

GEn1E Lifesciences'in YC başvurusu, yeniden yapılandırılmış

Y Combinator başvurusu

GEn1E Lifesciences, Summer 2019 dönemi. Gerçek form soruları, herkese açık verilerden yanıtlandı.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

GEn1E Lifesciences

Describe what your company does in 50 characters or less.

AI platform accelerating therapies for rare diseases

What is your company going to make? Please describe your product and what it does or will do.

We are building an AI platform that speeds up discovery and development of novel immunomodulatory therapies targeting multiple mechanisms at once. Our platform identifies and optimizes protein therapies for rare and inflammatory diseases with no current treatments. We've already developed a lead candidate for ARDS and a pipeline of 21+ selective immunomodulators.

Where do you live now, and where would the company be based after YC?

We live in Palo Alto, CA, and the company is based here.

Explain your decision regarding location.

Palo Alto puts us at the center of biotech and AI innovation, with access to top talent, investors, and collaborators. It's also where we're rooted personally and professionally.

Tam başvuruda 21 ek cevap

Founders, Progress, Idea, Equity, Curious, Batch Preference tam sürümde. YC Insights'ta, diğer her YC grubu yanında açmak için ücretsiz bir hesap oluşturun.

Tüm başvuruyu gör

Sıkça Sorulan Sorular

Bu, GEn1E Lifesciences şirketinin gerçek YC başvurusu mu?

Hayır. Y Combinator gönderilen başvuruları gizli tutar. Bu bir yeniden yapılandırmadır: gerçek YC form soruları, GEn1E Lifesciences'in kamuya açık verilerinden (lansman notları, kurucu geçmişleri, ürün açıklaması) yanıtlanmıştır. GEn1E Lifesciences gibi bir şirketin YC'ye kendisini nasıl sunacağını gösterir, gönderdikleri metni değil.